FindTrial
Sign In

A study to compare the effectiveness and safety of Desidustat tablets with another treatment (ESA) for anemia in patients with chronic kidney disease who are on peritoneal dialysis.

An Open-label, Randomised, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Erythropoietin stimulating agent (ESA) for the Treatment of Anemia in Patients with Chronic Kidney Disease (CKD) on Peritoneal Dialysis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077850
Enrollment
90
Registered
2024-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D631- Anemia in chronic kidney disease

Interventions

Intervention1: Desidustat: 100 mg tablet, Orally, Thrice weekly, post dialysis. frequency of dosing dependent on Hb level of patients. Control Intervention1: Erythropoietin stimulating agen: Dose is c

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: As per the protocol

Exclusion criteria

Exclusion criteria: As per the protocol

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of Desidustat Tablet versus Erythropoietin stimulating agent (ESA) based on change of hemoglobin (Hb) levels (evaluation versus baseline)Timepoint: To assess the efficacy of Desidustat Tablet versus Erythropoietin stimulating agent (ESA) based on change of hemoglobin (Hb) levels (evaluation versus baseline)—

Secondary

MeasureTime frame
To assess the effect of treatment of Desidustat Tablet as compared Erythropoietin stimulating agent (ESA)Timepoint: 24 weeks—

Countries

India

Contacts

Public ContactDr Indranil Ghosh

Army Hospital Research and Referral Hospital

rajpro_5@yahoo.com9876268895

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026